Latest Medical Cannabis News

Bioxyne Limited has delivered a record-breaking second quarter in FY2026, posting $17.2 million in revenue and expanding its footprint into key international markets. The company’s growth is underpinned by new contracts, innovative psychedelics products, and strategic government funding.

Argent BioPharma has signed a binding agreement to acquire AusCann’s 48% stake in CannPal, enhancing its clinical and intellectual property assets for CannEpil®. The deal includes an option for the Neuvis® drug-delivery platform and aligns with Argent’s U.S. dual-listing ambitions.

ECS Botanics reports a $218k positive operating cash flow in Q2 FY26, driven by strong B2C growth and new product launches. The company also secured $1.95 million in funding to fuel European expansion and product development.

ECS Botanics has achieved a milestone with direct-to-consumer sales exceeding 60% of total revenue, driven by the launch of innovative sugar-free THC gummies and a strategic distribution partnership.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has inked an exclusive deal to import, manufacture, and distribute Curaleaf’s Que Medical Inhalation Device in Australia, with a nationwide launch set for November 2025.

Cann Group Limited (ASX, CAN) launches a $2.5 million Share Purchase Plan offering eligible shareholders discounted shares and attaching options, supporting its recent debt restructure and growth ambitions.

Cann Group Limited reported a near break-even net operating cash flow for Q1 FY2026 and achieved its first EBITDA-positive month, setting the stage for a major debt restructure that will significantly reduce its borrowings.

Bioxyne Limited has secured import permits and purchase orders worth A$5.1 million for medical cannabis in Germany, signaling strong early traction in a key European market.

Bioxyne Limited projects FY2026 revenue between $65 million and $75 million, driven by expansion in Australian medical cannabis and a landmark $5.8 million contract in Germany.

Bioxyne Limited delivered a record FY25 with $30.4 million revenue, driven by Australian market growth and new European contracts. The company projects revenue up to $75 million in FY26, fueled by expanded production and international market entries.

Bioxyne Limited has reported record revenue and cash flow for FY25, driven by robust growth in the Australian medical cannabis market and strategic advances into Europe and the UK.

Bod Science Limited reports a dramatic reduction in half-year losses alongside revenue growth driven by a strategic shift to THC products. The company remains under a Deed of Company Arrangement with key corporate actions pending shareholder approval.